These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 33439474)
1. The Xyrem Strunc MJ; Black J; Lillaney P; Profant J; Mills S; Bujanover S; Thorpy MJ Drugs Real World Outcomes; 2021 Mar; 8(1):15-28. PubMed ID: 33439474 [TBL] [Abstract][Full Text] [Related]
2. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. Wang YG; Swick TJ; Carter LP; Thorpy MJ; Benowitz NL J Clin Sleep Med; 2009 Aug; 5(4):365-71. PubMed ID: 19968016 [TBL] [Abstract][Full Text] [Related]
3. The Xyrem risk management program. Fuller DE; Hornfeldt CS; Kelloway JS; Stahl PJ; Anderson TF Drug Saf; 2004; 27(5):293-306. PubMed ID: 15061684 [TBL] [Abstract][Full Text] [Related]
4. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321 [TBL] [Abstract][Full Text] [Related]
5. From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy. Fuller DE; Hornfeldt CS Pharmacotherapy; 2003 Sep; 23(9):1205-9. PubMed ID: 14524654 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union. Iranzo A; Serralheiro P; Schuller JC; Schlit AF; Bentz JWG Drugs Real World Outcomes; 2020 Dec; 7(4):307-315. PubMed ID: 32989679 [TBL] [Abstract][Full Text] [Related]
8. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Carter LP; Pardi D; Gorsline J; Griffiths RR Drug Alcohol Depend; 2009 Sep; 104(1-2):1-10. PubMed ID: 19493637 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. Xyrem International Study Group J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408 [TBL] [Abstract][Full Text] [Related]
12. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Santiago Ortiz AJ; Kesselheim AS JAMA Netw Open; 2022 Jan; 5(1):e2144386. PubMed ID: 35050352 [TBL] [Abstract][Full Text] [Related]
13. Sodium oxybate: a review of its use in the management of narcolepsy. Robinson DM; Keating GM CNS Drugs; 2007; 21(4):337-54. PubMed ID: 17381187 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of sodium oxybate as a treatment option for narcolepsy. Abad VC Expert Opin Pharmacother; 2019 Jul; 20(10):1189-1199. PubMed ID: 31136215 [No Abstract] [Full Text] [Related]
15. Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment. Tittarelli R; Pichini S; Pedersen DS; Pacifici R; Moresco M; Pizza F; Busardò FP; Plazzi G Forensic Sci Int; 2017 May; 274():70-74. PubMed ID: 28139340 [TBL] [Abstract][